

Title Page:

Title: High incidence of pulmonary thromboembolism in hospitalized SARS-CoV-2 infected patients

Authors: El-Qutob D¹ (ORCID 0000-0003-4837-782X), Alvarez L^{2,3} (ORCID 0000-0002-3745-4263), García-Sidro P⁴ (ORCID 0000-0002-4323-9201), Robustillo M⁵ (ORCID 0000-0001-5193-2500), Barreda I⁶ (ORCID 0000-0002-6129-639X), Nieto M¹ (ORCID 0000-0003-3968-510X), Pin M⁷ (ORCID 0000-0002-8971-1276), Carrera-Hueso FJ² (ORCID 0000-0002-4459-6059)

¹Unit of Allergy, University Hospital of La Plana in Vila-Real, Spain.

²Service of Pharmacy, University Hospital of La Plana in Vila-Real, Spain.

³Doctoral Program of Pharmacy, University of Granada, Spain.

⁴Section of Pneumology, University Hospital of La Plana in Vila-Real, Spain.

⁵Unit of Rheumatology, University Hospital of La Plana in Vila-Real, Spain.

⁶Section of Neurophysiology, University Hospital of La Plana in Vila-Real, Spain.

⁷Unit of Nephrology, University Hospital of La Plana in Vila-Real, Spain.

***Corresponding author**

David El-Qutob, Unit of Allergy, University Hospital of La Plana in Vila-Real, Spain

Carretera Vila-Real-Burriana Km. 0.5 Vila-Real (Castellon) 12540, Spain

Tel. 00 34 964399961

Fax: 00 34 964 35 76 01

elqutob@comv.es

Acknowledgement

This paper is part of thesis doctoral of Laura Álvarez in University of Granada (Spain), Doctoral Pharmacy Program at Pharmacy Department.

A sincere thank you to Juan Pablo Fernandez for his diligent proofreading of this paper.

Abstract

Introduction

SARS-CoV-2 infected patients present thrombotic complications caused by direct endothelial cells injury of the microvessels. Pulmonary thromboembolism (PE) has been reported by Computed Tomography pulmonary angiogram (CTPA) in patients with COVID-19 pneumonia with high D-dimer levels.

Objectives

We present the characteristics of SARS-CoV-2 infected patients diagnosed of PE by CTPA in our hospital. We also present the comparison of these findings with non-infected patients with PE data.

Methods

Patients 18 years of age or older with SARS-CoV2 virus infection, and patients with suspected infection at beginning of admission but with negative PCR, were studied with CTPA for suspicion of VTE, during their hospitalization.

Results

During the study period, 52 CTPA were performed in our hospital, sixteen in SARS-CoV-2 infected patients. No significant differences in age ($p=0.43$) and sex ($p=0.31$) were found between the two groups, infected and non-infected patients. In the infected group, the patients who had PE had a much lower median age (47.8 years) than those without PE (73.3 years). No differences between infected and non-infected patients were detected in the diagnosis of PE with CTPA, 28.6% versus 27.8% ($p=1.00$). Overall patient mortality was 1.9%; one patient died (6.3%) in the infected group, and none in the non-infected group ($p=0.31$).

Conclusion

A considerable incidence of PE diagnosed by CTPA in SARS-CoV-2 infected patients has been observed, despite thrombo-prophylaxis.

Keywords: coronavirus, COVID-19, SARS-CoV-2, coagulation, thrombosis, thromboembolism

Introduction

The outbreak of the COVID-19 pandemic, caused by the novel coronavirus Severe Acute Respiratory Syndrome-CoronaVirus-2 (SARS-CoV-2), in the city of Wuhan, Hubei province of China, was declared by the World Health Organization (WHO) on March 21st. Thrombotic complications are an important issue in patients infected with COVID-19. Pulmonary thromboembolism (PE) has been reported by computed tomography pulmonary angiogram (CTPA) in patients with COVID-19 pneumonia with high D-dimer levels¹ and in COVID-19 patient with normal D-dimer level, without strong predisposing risk factors for venous thrombo-embolism (VTE)².

SARS-CoV-2 binds Angiotensin-converting enzyme 2 receptors through the viral surface spike protein and gain entry to cells. This protein, higher in individuals with cardiovascular disease, is linked by plasmin, and potentially making them more susceptible to worse outcomes³. This pattern of prothrombotic coagulopathy is different from what noticed in sepsis, where thrombocyte count is usually decreased, and of disseminated intravascular coagulation, where the exhausted coagulation system shows a prolongation of the prothrombin time and aPTT (activated Partial Thromboplastin Time), and a haemorrhagic tendency⁴. SARS-CoV-2 infection is suspected of producing deregulation of the coagulation system, with formation of intra-alveolar or systemic fibrin clots, associated with severe respiratory disease⁵. SARS-CoV-2 produces direct endothelial cells injury of the microvessels and then releases these damaged endothelial cells into the circulation⁶. PE has been reported in patients suffering from SARS-CoV-2 infection (2). Moreover, microthrombosis of small pulmonary vessels has been observed in the post-mortem inspection of lungs⁷. Immobilization due to prolonged intensive care unit (ICU) admission in severely infected patients as well as a hypercoagulable state caused by SARS-CoV-2, may be relevant factors.

Consequently, PE may be considered in SARS-CoV-2 infected patients with abrupt onset of oxygenation desaturation, respiratory distress, and decreased blood pressure⁸. This possibility might be suspected also by elevated D-dimer values, even though D-dimer is a non-specific acute phase reactant. However, other authors argued that there is no evidence for use of biomarkers such as D-dimer to guide intensification of anticoagulant dosing despite it being a marker of poor prognosis⁹.

In a recent study investigating the prognostic factors of 28-day mortality of severely SARS-CoV-2 infected patients, the use of anticoagulant therapy for at least seven days, resulted in lower mortality in patients with D-dimer over six fold the upper limit of normal (Low Molecular Weight Heparin (LMWH): 32.8% vs No-LMWH: 52.4%, $P=0.017$), but without overall benefit for patients on LMWH⁷. A recent study examined two groups of patients: those with COVID-19 and those without COVID-19. The COVID-19 group showed lower mortality rates with heparin administration (LMWH (40–60 mg enoxaparin/day) or unfractionated heparin (UFH) (10,000–15,000 U/day)) than those without heparin. Interestingly, there was no difference in mortality in the COVID-19 negative patients with the use of heparin¹⁰. Our goal is to analyze the characteristics of SARS-CoV-2 infected patients diagnosed of PE by CTPA in our hospital.

Methods

Study population

Patients 18 years of age or older with SARS-CoV2 virus infection confirmed by diagnostic test of reverse transcription of polymerase chain reaction (RT-qPCR) in a sample of nasopharyngeal or sputum aspirate, and patients with suspected infection at beginning of admission but with negative PCR, who were studied with CTPA for suspicion of VTE, during their ward admission to an European Hospital from February 26th- to May 20th of 2020.

Patients who denied consent for CTPA, and pregnant or breastfeeding women were excluded from the study. Patients who were re-admitted at the hospital for any reason were also excluded, and only the first episode of hospitalization was considered. Our routine protocol for patients with severe clinical features of COVID-19 infection was multidetector pulmonary CT angiography using 16 slice multi-detector CT (GE Healthcare, Milwaukee, WI) after intravenous injection of 60 ml iodinated contrast agent (Iohexol 350 mg/mL, GE Healthcare, Milwaukee, WI) at a flow rate of 3.5 mL/s, triggered on the main pulmonary artery.

Demographic data, comorbidities, clinical symptoms, laboratory results, radiological tests and treatment of each patient were evaluated. A data collection sheet was created in Microsoft Excel where all variables were automatically collected. Statistical analysis and processing of the data was carried out using the SPSS

version 19 statistical package (IBM Corp. Released 2010. IBM SPSS Statistics for Windows, Version 19.0. Armonk, NY: IBM Corp.). Categorical variables are represented as absolute frequencies and percentages, and quantitative variables are expressed by median and Interquartile Range (IQR) calculated by Tukey's Hinges method. The difference analysis used student's T test for variables or the Mann-Whitney test if they have normal distribution or not respectively. To contrast the categorical variables, the test of chi-squared test (χ^2) The statistical significance level adopted for all contrast tests was $p < 0.05$.

Results

During the study period, 52 CTPA were performed in our hospital, sixteen in SARS-CoV-2 infected patients with positive RT-qPCR test. The median age of all patients included in the study was 70.1 years (Interquartile range (IQR): 55.7 to 83.3) and 27 (51.9%) were male. No significant differences in age ($p=0.43$) and sex ($p=0.31$) were found between the two groups, infected and non-infected patients. However, in the infected group, the patients who had PE had a much lower median age (47.8 years) than those without PE (73.3 years). Table 1 shows the demographic and comorbidities of the patients. The most common comorbidities were hypertension (71.2%), hyperlipidaemia (48.1%), diabetes (34.6%) and obesity (36.5%). In the non-infected group, congestive heart failure (27.8%, $p=0.02$) and previous treatment with anticoagulants (22.2%, $p=0.04$) were more significantly frequent than in the infected group.

The median of total comorbidities was 2.5 (IQR:1.0 to 3.5) and 4.0 (IQR: 2.0 to 6.0) for infected and non-infected patients, respectively ($p=0.07$), and for all the patients was 3 (IQR: 2.0 to 5.5). According to the Charlson Comorbidity Index abbreviated, 53.8% of the patients ($n=28$) do not have comorbidities.

The most common symptoms were fever, dyspnea, malaise, and cough (see Table 2). Fever was more common in the infected group with statistically significant difference (75.0% versus 41.7%, $p=0.03$).

Abnormal chest X-ray was observed in most patients at admission. Radiological findings are showed in Table 3. Chest CT scan was significantly different between infected and non-infected patients ($p < 0.01$). The most common abnormality was ground-glass opacities in both groups, being more frequent in the infected group

than in the non-infected (50% vs 11%). No differences between infected and non-infected patients were detected in the diagnosis of PE with CTPA, 28.6% versus 27.8% ($p=1.00$). Bilateral affection ($p=0.01$), and the parenchymal lesion $p<0.01$ were significantly more frequent in the infected group (The median of hospitalization days before CTPA was performed, was 3.5 days (IQR: 1.0 to 9.0); being 2 (IQR: 0.5 to 6.0) and 9.5 (IQR: 3.5 to 13.0) for the non-infected group and infected group, respectively).

Table 4 shows the laboratory findings before CTPA. The most relevant laboratory findings were lymphopenia, lengthening of the prothrombin time, elevated LDH, D-dimer and ferritin. Figure 1 shows the levels of D-dimer categorized by groups and result of PE. Among the patients who had PE, statistically significant differences were found in the levels of total CK ($p = 0.01$) and troponin T ($p = 0.02$), being higher in the infected group compared to the non-infected.

Fifty patients (96.2%) were treated with LMWH. Thirty-two patients (61.5%) received subcutaneous heparin at prophylactic doses, and 20 patients (38.5%) therapeutic doses. In the infected group, the use of heparin at prophylactic doses was more common than in the non-infected group ($p=0.01$). The overall median duration of treatment with LMWH was 11 days (IQR: 6.5 to 17.0).

Overall patient mortality was 1.9%; one patient died (6.3%) in the infected group, and none in the non-infected group ($p=0.31$).

Discussion

We present our case series of patients with and without SARS-CoV-2 infection, who were studied by CTPA on suspicion of pulmonary thromboembolism (PE).

There have been several groups that have published their results studying SARS-CoV-2 infected patients with a suspicion of pulmonary embolus. Leonard-Lorant *et al* observed positive CTPA angiography for PE in thirty-two of 106 (30% [95%CI: 22-40%])¹¹, with higher D-dimer levels than those without pulmonary embolus. They also observed that D-dimer greater than 2660 $\mu\text{g/L}$ had a sensitivity of 32/32 (100%, 95%CI: 88-100) and a specificity of 49/74 (67%, 95% CI: 52-79) for pulmonary embolism on CTPA. Stoneham *et al* diagnosed 21 out of 274 (7.7%) patients with VTE, 16 with PE (5.83%)¹². They found significance differences in levels of D-dimer

and white cell count but not in age, gender, or presence of comorbidities between PE patients and control group. Klok *et al* detected 25 symptomatic VTE events in 184 adult patients admitted in three ICU across the Netherlands¹³. A similar study of 150 critical patients from four ICUs in France, found 16.7% of patients with PE despite the anticoagulant therapy¹⁴. In the study of Middeldorp *et al* 39 patients (19.6%) were diagnosed with VTE, despite routine thrombosis prophylaxis¹⁵. Lodigiani *et al* detected PE in 10 (33%) of CTPA performed¹⁶. Grillet *et al* studied one hundred patients with severe respiratory COVID disease and/or comorbidities by CTPA¹⁷. Twenty-three (23%, [95% CI: 15-33%]) patients had acute PE. Compared with patients without PE, these patients were admitted in ICU and required mechanical ventilation more frequently.

We have detected PE in 28.6% of infected patients who were studied with CTPA. All these studies revealed the importance of early onset of anticoagulant therapy. In fact, chronic anticoagulation therapy at admission has been associated with a lower risk of the composite outcome (Hazard Ratio [HR] 0.29, 95%CI: 0.091–0.92), and patients diagnosed with thrombotic complications are at higher risk of all-cause death (HR 5.4; 95%CI: 2.4–12)¹⁸. Some authors have highlighted the possibility that some individuals infected with COVID-19 may be refractory to treatment with low molecular weight heparin, and it has been studied the use of tissue plasminogen activator in these cases¹⁹.

The main clinical symptoms of COVID-19 patients in the study of Li *et al*, similar as our results, were fever (88.5%), cough (68.6%), myalgia or fatigue (35.8%), expectoration (28.2%), and dyspnea (21.9%)²⁰.

We have not seen differences in mortality between both groups. However, patients with COVID-19 infection, with a high risk of venous thromboembolism, had poorer outcomes than patients with a low risk, suggesting that these patients might require increased attention in case of rapid deterioration²¹. Global mortality rates of SARS-CoV-2 infection has been established in 5.7%²², while our overall mortality was 1.9%.

The statistically significant differences detected in infected and non-infected PE patients in total CK and troponin T levels should lead us to consider the presence of myocardial damage caused by SARS-CoV-2, which is not found in uninfected PE patients.

Based on our data and experience, LMWH therapy should be considered, with at least prophylactic dose, in all patients with COVID-19 pneumonia for a longer period than required for clinical resolution of the disease, considering the high risk of thromboembolic complications of SARS-CoV-2 infection. Additionally, CTPA is the cornerstone in both the diagnostic workup and follow-up of SARS-CoV-2 infection. The main limitations of our study are the small sample size, and the lack of generalized study with CTPA in all the admitted COVID patients at hospital. It is possible that our incidence of PE, as in other studies, is probably highly underestimated due to the paucity of CTPA performed for PE during hospitalization, and most of the studies included only critical patients in Intensive Care Unit (ICU). In fact, the risk for VTE in COVID-19 patients is high, particularly in ICU patients. We therefore cannot establish a realistic prevalence for PE in all our COVID patients. Another limitation is the possible bias of patient selection by incorporating only the most severe or expected diagnosis of PE results, but this has been attempted to control by consecutive incorporation of all CTPA performed. A considerable incidence of PE diagnosed by CTPA in SARS-CoV-2 infected patients in our hospital has been observed, despite thrombo-prophylaxis. The infected patients with PE should be examined for assessing myocardial damage.

Ethical Approval

The local ethics committee approved this study (approved May 25, 2020) and waived the need of informed consent. Personal data were dissociated and pseudoanonymized in the database for further statistical analysis by an independent expert.

Authors Contributions

DE had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. FJCH and LA contributed substantially to study design, data collection and data analysis. All authors helped with study interpretation, writing, and editing of the manuscript.

Funding

The authors do not declare any funding sources for this article.

Competing Interests

Authors have nothing to disclose.

Availability of data and materials

Data and material cannot be showed.

References

1. Darzi AJ, Karam SG, Charide R, et al. Prognostic factors for VTE and bleeding in hospitalized medical patients: a systematic review and meta-analysis. *Blood* 2020; **135**(20): 1788-810.
2. Anderson DR, Morgano GP, Bennett C, et al. American Society of Hematology 2019 guidelines for management of venous thromboembolism: prevention of venous thromboembolism in surgical hospitalized patients. *Blood advances* 2019; **3**(23): 3898-944.
3. Khan IH, Savarimuthu S, Tsun Leung MS, Harky A. The need to manage the risk of thromboembolism in COVID-19 patients. *Journal of vascular surgery* 2020.
4. Ranucci M, Ballotta A, Di Dedda U, et al. The procoagulant pattern of patients with COVID-19 acute respiratory distress syndrome. *Journal of thrombosis and haemostasis : JTH* 2020.
5. Giannis D, Ziogas IA, Gianni P. Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past. *Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology* 2020; **127**: 104362.
6. An P, Ye Y, Chen M, Chen Y, Fan W, Wang Y. Management strategy of novel coronavirus (COVID-19) pneumonia in the radiology department: a Chinese experience. *Diagnostic and interventional radiology (Ankara, Turkey)* 2020; **26**(3): 200-3.

7. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. *Journal of thrombosis and haemostasis : JTH* 2020; **18**(5): 1094-9.
8. Scialpi M, Scialpi S, Pisciolli I, Battista Scalera G, Longo F. Pulmonary thromboembolism in critical ill COVID-19 patients. *International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases* 2020; **95**: 361-2.
9. Barnes GD, Burnett A, Allen A, et al. Thromboembolism and anticoagulant therapy during the COVID-19 pandemic: interim clinical guidance from the anticoagulation forum. *Journal of thrombosis and thrombolysis* 2020: 1-10.
10. Yin S, Huang M, Li D, Tang N. Difference of coagulation features between severe pneumonia induced by SARS-CoV2 and non-SARS-CoV2. *Journal of thrombosis and thrombolysis* 2020: 1-4.
11. Leonard-Lorant I, Delabranche X, Severac F, et al. Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels. *Radiology* 2020: 201561.
12. Stoneham SM, Milne KM, Nuttal E, et al. Thrombotic risk in COVID-19: a case series and case-control study. *Clinical medicine (London, England)* 2020.
13. Klok FA, Kruip M, van der Meer NJM, et al. Incidence of thrombotic complications in critically ill ICU patients with COVID-19. *Thrombosis research* 2020.
14. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study. *Intensive care medicine* 2020; **46**(6): 1089-98.
15. Middeldorp S, Coppens M, van Haaps TF, et al. Incidence of venous thromboembolism in hospitalized patients with COVID-19. *Journal of thrombosis and haemostasis : JTH* 2020.

16. Lodigiani C, Iapichino G, Carenzo L, et al. Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in Milan, Italy. *Thrombosis research* 2020; **191**: 9-14.
17. Grillet F, Behr J, Calame P, Aubry S, Delabrousse E. Acute Pulmonary Embolism Associated with COVID-19 Pneumonia Detected by Pulmonary CT Angiography. *Radiology* 2020: 201544.
18. Klok FA, Kruip M, van der Meer NJM, et al. Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis. *Thrombosis research* 2020.
19. Wang J, Hajizadeh N, Moore EE, et al. Tissue plasminogen activator (tPA) treatment for COVID-19 associated acute respiratory distress syndrome (ARDS): A case series. *Journal of thrombosis and haemostasis : JTH* 2020.
20. Li LQ, Huang T, Wang YQ, et al. COVID-19 patients' clinical characteristics, discharge rate, and fatality rate of meta-analysis. *Journal of medical virology* 2020; **92**(6): 577-83.
21. Wang T, Chen R, Liu C, et al. Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19. *The Lancet Haematology* 2020; **7**(5): e362-e3.
22. Baud D, Qi X, Nielsen-Saines K, Musso D, Pomar L, Favre G. Real estimates of mortality following COVID-19 infection. *The Lancet Infectious diseases* 2020.

Table 1. Demographic characteristics and comorbidities of the patients stratified by negative or positive infection

N (%)	TOTAL (n=52)	Infected Group (n=16)		Non-infected Group (n=36)	
		TEP (n=4)	Not TEP (n=12)	TEP (n=11)	Not TEP (n=27)
Age in years, median (range)	70.1 (55.7-83.3)	47.8 (43.6-63.4)	73.3 (57.5-84.0)	68.6 (59.9-77.2)	76.3 (62.3-83.1)
Sex					
Male	27 (51.9)	1 (25.0)	5 (41.7)	5 (45.5)	14 (51.9)
Female	25 (48.1)	3 (75.0)	7 (58.3)	6 (54.5)	13 (48.1)
Hypertension	37 (71.2)	2 (50.0)	9 (75.0)	7 (63.6)	21 (77.8)
Diabetes	18 (34.6)	1 (25.0)	3 (25.0)	4 (36.4)	11 (40.7)
Coronary heart disease	8 (15.4)	0(0.0)	2 (16.7)	2 (18.2)	4 (14.8)
Chronic kidney disease	10 (19.2)	0 (0.0)	2 (16.7)	2 (18.2)	6 (22.2)
COPD	4 (7.7)	1 (25.0)	0(0.0)	1 (9.1)	2 (7.4)
Asthma	5 (9.6)	0 (0.0)	1 (8.3)	2 (18.2)	2 (7.4)
Other Chronic Lung Diseases	8 (15.4)	0 (0.0)	1 (8.3)	1 (9.1)	6 (22.2)
Congestive heart failure	10 (19.2)	--	--	1 (9.1)	9 (33.3)
Malignancy tumor	12 (23.1)	1 (25.0)	2 (16.7)	2 (18.2)	7 (25.9)
Cardiovascular disease	17 (32.7)	0 (0.0)	3 (25.0)	2 (18.2)	12 (44.4)
Cerebrovascular disease	4 (7.7)	0 (0.0)	1 (8.3)	0 (0.0)	3 (11.1)
Hyperlipidemia	25 (48.1)	1 (25.0)	5 (41.7)	5 (45.5)	15 (55.6)
Smoking History:					
Never smoker	34 (65.4)	2 (50.0)	6 (50.0)	7 (63.6)	20 (74.1)
Current smoker	9 (17.3)	1 (25.0)	3 (25.0)	1 (9.1)	4 (14.8)
Former smoker	9 (17.3)	1 (25.0)	3 (25.0)	3 (27.3)	3 (11.1)
Obesity (IMC≥30 Kg/m2)	19 (36.5)	2 (50.0)	3 (25.0)	6 (54.5)	9 (33.3)
Dementia	3 (5.8)	0 (0.0)	1 (8.3)	1 (9.1)	1 (3.7)
Anticoagulant treatment	8 (15.4)	--	--	1 (9.1)	8 (29.6)
ACEI or ARB	29 (55.8)	3 (75.0)	8 (66.7)	5 (45.5)	13 (48.1)

*ACE: Angiotensin-converting enzyme inhibitors, ARB: Angiotensin II receptor-blockers.

Table 2. Signs and symptoms of the patients on admission

N (%)	TOTAL (n=52)	Infected Group (n=16)		Non-infected Group (n=36)	
		TEP (n=4)	Not TEP (n=12)	TEP (n=11)	Not TEP (n=27)
Fever	27 (51.9)	3 (75.0)	9 (75.0)	4 (36.4)	11 (40.7)
Dyspnea	28 (53.8)	2 (50.0)	6 (50.0)	5 (45.5)	15 (55.6)
Cough	18 (34.6)	2 (50.0)	4 (33.3)	4 (36.4)	9 (33.3)
Expectoration	5 (9.6)	0 (0.0)	1 (8.3)	1 (9.1)	4 (14.8)
Sore throat	3 (5.8)	--	--	0 (0.0)	3 (11.1)
Myalgia	9 (17.3)	1 (25.0)	2 (16.7)	4 (36.4)	3 (11.1)
Headache	2 (3.8)	--	--	1 (9.1)	1 (3.7)
Dizziness	6 (11.5)	0 (0.0)	2 (16.7)	0 (0.0)	4 (14.8)
Diarrhea	7 (13.5)	1 (25.0)	2 (16.7)	0 (0.0)	4 (14.8)
Chest pain	6 (11.5)	0 (0.0)	1 (8.3)	1 (9.1)	4 (14.8)
Malaise	21 (40.4)	2 (50.0)	7 (58.3)	3 (27.3)	9 (33.3)
Anosmia	2 (3.8)	1 (25.0)	1 (8.3)	--	--
Dysgeusia	3 (5.8)	1 (25.0)	1 (8.3)	0 (0.0)	1 (3.7)

Table 3. Radiological findings.

N (%)	TOTAL (N=52)	Infected Group (n=16)		Non-infected Group (n=36)	
		TEP (n=4)	Not TEP (n=12)	TEP (n=11)	Not TEP (n=27)
Chest X-ray					
Normal	16 (30.8)	2 (50.0)	1 (8.3)	7 (63.6)	9 (33.4)
Opacities	12 (23.1)	1 (25.0)	7 (58.3)	1 (9.1)	3 (11.1)
Interstitial pattern	9 (17.3)	1 (25.0)	4 (33.3)	1 (9.1)	3 (11.1)
No COVID Injuries	14 (26.9)	0 (0.0)	0 (0.0)	2 (18.2)	12 (44.4)
CTPA					
Bilateralism	32 (61.5)	4 (100.0)	10 (83.3)	10 (90.9)	9 (33.3)
Parenchymal injury	14 (26.9)	2 (50.0)	7 (58.3)	3 (27.3)	2 (7.4)
Pleural effusion	19 (36.5)	0 (0.0)	5 (41.7)	0 (0.0)	14 (51.9)
Pericardial effusion	4 (7.7)	0 (0.0)	1 (8.3)	0 (0.0)	3 (11.1)
Metastasis	3 (5.8)	0 (0.0)	1 (8.3)	1 (9.1)	1 (3.7)

Table 4 Laboratory results before CTPA

Laboratory results, median (IQR)	TOTAL (N=52)	Infected Group (n=16)		Non-infected Group (n=36)		Reference ranges
		TEP (n=4)	Not TEP (n=12)	TEP (n=11)	Not TEP (n=27)	
White blood cell count, x 10 ⁹ /L	7.6 (5.9-9.8)	7.7 (6.3-9.1)	6.7 (4.3-8.4)	9.0 (6.8-12.1)	7.7 (5.5-9.9)	4.8-11
Hemoglobin, g/dL	12.7 (11.1-14.3)	11.8 (10.9-12.6)	12.7 (12.6-14.7)	12.9 (10.4-14.1)	12.9 (11.0-14.2)	12-18
Neutrophil count, x 10 ⁹ /L	5.4 (3.3-8.0)	5.3 (4.2-6.3)	4.9 (1.7-5.4)	7.2 (5.4-9.2)	5.5 (3.1-8.0)	1.9-8
Lymphocyte count, x 10 ⁹ /L	1.30 (0.95-1.65)	1.3 (1.0-1.6)	1.4 (1.0-1.7)	1.0 (0.7-1.8)	1.3 (1.0-1.6)	0.9-4.5
Platelet count, x 10 ⁹ /L	204 (160-255)	178 (152-204)	263 (225-276)	199 (174-312)	198 (146-222)	130-400
D-dimer, µg/mL	2323.5 (1083.0-7301.5)	5824.5 (5120.0-6523.0)	1573.0 (1041.0-5873.0)	5078.5 (2258.0-12721.0)	1731.0 (1007.5-2494.5)	0-500
Prothrombin time, sec	12.5 (11.6-13.3)	12.7 (12.0-13.4)	11.7 (11.4-13.2)	12.5 (11.2-12.9)	13.0 (12.1-13.4)	9-13
Glucose, mg/dL	118 (94-145)	112 (109-115)	102 (92-124)	139 (118-181)	105 (92-141)	82-115
Creatinine, mg/dL	0.91 (0.76-1.10)	1.40 (1.08-1.72)	0.81 (0.68-0.87)	0.90 (0.70-0.99)	0.94 (0.83-1.15)	0.7-1.2
Total bilirubin, mg/dL	0.40 (0.28-0.55)	0.34 (0.20-0.48)	0.47 (0.31-0.60)	0.29 (0.22-0.45)	0.41 (0.36-0.59)	0.1-1.2
Sodium, mmol/L	140.2 (138.0-142.6)	143.5 (142.2-144.8)	142.0 (140.0-143.0)	139.4 (138.5-142.6)	139.7 (136.1-142.0)	136-146
Potassium, mmol/L	4.52 (4.08-4.80)	5.62 (4.61-6.62)	4.40 (4.09-4.67)	4.27 (4.01-4.47)	4.57 (4.23-4.91)	3.5-5.1
Alanine aminotransferase (GPT), U/L	21.5 (12.8-38.4)	9.0 (8.3-9.6)	36.3 (23.7-73.1)	22.3 (17.2-28.3)	18.7 (9.9-37.9)	5-41
Lactate dehydrogenase, U/L	223 (199-262)	273 (197-348)	231 (204-260)	223 (208-237)	231 (164-276)	135-225
CK total, U/L	61.0 (4.5-91.5)	135.5 (102.0-169.0)	61.0 (45.0-78.5)	87 (33-99)	50 (29-66)	24-192
C- reactive protein, mg/dL	2.00 (0.85-5.03)	1.87 (0.62-3.11)	1.04 (0.45-4.95)	2.77 (1.28-4.02)	2.06 (1.17-5.59)	0.1-1
Procalcitonin, ng/mL	0.068 (0.048-0.124)	0.079 (0.073-0.084)	0.048 (0.048-0.068)	0.062 (0.058-0.131)	0.081 (0.048-0.124)	0-0.5
Ferritin, ng/mL	269.1 (179.4-955.6)	128.1 (36.3-219.8)	735.4 (185.4-1170.4)	288.3 (221.5-682.7)	269.1 (174.3-1057.9)	30-400
Troponine T, pg/mL	15.18 (8.98-33.22)	71.14 (50.87-91.40)	6.37 (5.13-8.75)	24.53 (11.77-46.18)	14.77 (10.76-27.04)	<14